{"id":"hydrochlorothiazide-hct","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Hypokalemia"},{"rate":"5-10","effect":"Hyperglycemia"},{"rate":"5-10","effect":"Hyperuricemia"},{"rate":"1-5","effect":"Hyponatremia"},{"rate":"5-10","effect":"Hypotension"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Photosensitivity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a thiazide diuretic, HCT blocks the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, preventing reabsorption of sodium and chloride. This osmotic effect increases urine output and reduces plasma volume, leading to decreased cardiac preload and peripheral vascular resistance. The resulting blood pressure reduction makes it effective for hypertension management, often as a first-line agent.","oneSentence":"Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule of the kidney, promoting water and electrolyte excretion to reduce blood volume and blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:31:32.543Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Edema associated with congestive heart failure"},{"name":"Edema associated with renal disease"},{"name":"Edema associated with hepatic cirrhosis"}]},"trialDetails":[{"nctId":"NCT07458880","phase":"NA","title":"Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-01","conditions":"Intracerebral Hemorrhage","enrollment":140},{"nctId":"NCT02483936","phase":"PHASE3","title":"Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"","conditions":"Arterial Hypertension","enrollment":""},{"nctId":"NCT02493322","phase":"PHASE3","title":"Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"","conditions":"Essential Arterial Hypertension","enrollment":""},{"nctId":"NCT04654312","phase":"PHASE1","title":"Study to Evaluate the Influence of Hydrochlorothiazide on Dermal Photosensitivity and DNA Stability - a Pilot Study (HCTox Study)","status":"COMPLETED","sponsor":"Universität des Saarlandes","startDate":"2021-01-18","conditions":"Photosensitivity","enrollment":30},{"nctId":"NCT05920005","phase":"PHASE3","title":"Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-08-22","conditions":"Hypertension","enrollment":702},{"nctId":"NCT06710600","phase":"NA","title":"Phototoxicity of Frequently Prescribed Medicines","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2022-09-22","conditions":"Phototoxicity","enrollment":12},{"nctId":"NCT00649688","phase":"PHASE1","title":"Fasting Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg and Lopressor HCT® Tablets 100/50 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2003-01","conditions":"Healthy","enrollment":32},{"nctId":"NCT00649597","phase":"PHASE1","title":"Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-11","conditions":"Healthy","enrollment":56},{"nctId":"NCT00649233","phase":"PHASE1","title":"Food Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg to Lopressor HCT® Tablets 100/50 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2003-01","conditions":"Healthy","enrollment":32},{"nctId":"NCT00649038","phase":"PHASE1","title":"Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-12","conditions":"Healthy","enrollment":24},{"nctId":"NCT01019590","phase":"PHASE1","title":"Fed Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2006-11","conditions":"Healthy","enrollment":36},{"nctId":"NCT01020214","phase":"PHASE1","title":"Fasting Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2006-11","conditions":"Healthy","enrollment":36},{"nctId":"NCT05443932","phase":"PHASE4","title":"Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2024-03-04","conditions":"Urolithiasis, Hyperoxaluria","enrollment":32},{"nctId":"NCT03254849","phase":"PHASE4","title":"Empagliflozin and Sympathetic Nerve Traffic","status":"COMPLETED","sponsor":"Profil Institut für Stoffwechselforschung GmbH","startDate":"2017-12-08","conditions":"Type 2 Diabetes Mellitus","enrollment":75},{"nctId":"NCT04242758","phase":"PHASE4","title":"Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy","status":"UNKNOWN","sponsor":"University of Pisa","startDate":"2019-06-04","conditions":"Renal Function Disorder, Glucose Metabolism Disorders","enrollment":30},{"nctId":"NCT01070030","phase":"PHASE4","title":"Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-01","conditions":"Stage II Hypertension","enrollment":230},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT01879527","phase":"PHASE2","title":"Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2014-03","conditions":"Optic; Neuritis, With Demyelination","enrollment":78},{"nctId":"NCT00274638","phase":"PHASE4","title":"PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-07","conditions":"Hypertension","enrollment":805},{"nctId":"NCT00240448","phase":"PHASE4","title":"A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-09","conditions":"Hypertension","enrollment":1109},{"nctId":"NCT01087749","phase":"PHASE1","title":"Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-03","conditions":"Kidney Disease","enrollment":24},{"nctId":"NCT00996281","phase":"PHASE3","title":"Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-10","conditions":"Essential Hypertension","enrollment":837},{"nctId":"NCT00775814","phase":"PHASE4","title":"Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-10","conditions":"Obesity, Hypertension","enrollment":188},{"nctId":"NCT00846365","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-03","conditions":"Essential Hypertension","enrollment":1085},{"nctId":"NCT01033071","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-01","conditions":"Essential Hypertension","enrollment":1071},{"nctId":"NCT01180205","phase":"PHASE4","title":"Telmisartan, Amlodipine and Flow Mediated Dilation","status":"UNKNOWN","sponsor":"Johannes Gutenberg University Mainz","startDate":"2010-08","conditions":"Hypertension","enrollment":576},{"nctId":"NCT00277472","phase":"PHASE4","title":"Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-11","conditions":"Hypertension","enrollment":300},{"nctId":"NCT00446563","phase":"PHASE3","title":"Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-03","conditions":"Hypertension; Hypertrophy, Left Ventricular","enrollment":90},{"nctId":"NCT00434967","phase":"PHASE3","title":"Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Hypertension","enrollment":2207},{"nctId":"NCT00621153","phase":"PHASE4","title":"Candesartan Effect in Second Stage Arterial Hypertension","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-02","conditions":"Stage II Hypertension","enrollment":214},{"nctId":"NCT00160160","phase":"NA","title":"Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2004-10","conditions":"Hypertension, Type 2 Diabetes","enrollment":440},{"nctId":"NCT00687206","phase":"PHASE4","title":"Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Patients With Slight Hypertension and Target Organ Damage","status":"COMPLETED","sponsor":"Federico II University","startDate":"2008-03","conditions":"Hypertension, Ventricular Remodeling, Erectile Dysfunctions","enrollment":20},{"nctId":"NCT00778726","phase":"NA","title":"Bioequivalence Study of Benazepril HCl / Hydrochlorothiazide 20 mg/ 25 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2004-09","conditions":"Healthy","enrollment":42},{"nctId":"NCT00777972","phase":"NA","title":"Bioequivalence Study of Fosinopril Sodium/ Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2003-03","conditions":"Healthy","enrollment":34},{"nctId":"NCT00778674","phase":"NA","title":"Bioequivalence Study of Benazepril HCl / Hydrochlorothiazide 20 mg/ 25 mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2004-10","conditions":"Healthy","enrollment":30},{"nctId":"NCT00778713","phase":"NA","title":"Bioequivalence Study of Fosinopril Sodium / Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2003-03","conditions":"Healthy","enrollment":33},{"nctId":"NCT00383929","phase":"PHASE3","title":"Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Hypertension","enrollment":1979},{"nctId":"NCT00607633","phase":"","title":"Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Essential Hypertension, Left Ventricular Hypertrophy","enrollment":686},{"nctId":"NCT00608153","phase":"","title":"Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Essential Hypertension","enrollment":1773},{"nctId":"NCT00185068","phase":"PHASE4","title":"An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2004-03","conditions":"Hypertension","enrollment":110}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"GASTROINTESTINAL HAEMORRHAGE"},{"count":2,"reaction":"PRURITUS"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"ANAPHYLACTIC SHOCK"},{"count":1,"reaction":"ANGIOEDEMA"},{"count":1,"reaction":"BLOOD URINE PRESENT"},{"count":1,"reaction":"BONE MARROW DEPRESSION"},{"count":1,"reaction":"BRONCHITIS CHRONIC"},{"count":1,"reaction":"CARDIAC FAILURE"},{"count":1,"reaction":"CEREBROVASCULAR ACCIDENT"}],"_approvalHistory":[],"publicationCount":338,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Hydrochlorothiazide (HCT)","genericName":"Hydrochlorothiazide (HCT)","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule of the kidney, promoting water and electrolyte excretion to reduce blood volume and blood pressure. Used for Hypertension, Edema associated with congestive heart failure, Edema associated with renal disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}